Evidence map›Paper›PMID 37081824›Full record

ArticleMolecular oncology2023

The invariant chain CD74 protein is a cell surface binding partner of TIMP-1 in breast cancer cells.

Mikkel Høeberg, Julie Boertmann Noer, Mette Vixø Vistesen, Annette Bartels, Esben Matzen Bech, Sune Boris Nygård, Ulrik Lademann, Jan Stenvang, Siqi Liu, Anja Thoe Fuglsang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Substrate O-glycosylation actively regulates extracellular proteolysis.Protein science : a publication of the Protein Society · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Mikkel HøebergDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Julie Boertmann NoerDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Mette Vixø VistesenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Annette BartelsDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Esben Matzen BechTransport Biology section, Department of Plant and Environmental Sciences, University of Copenhagen, Denmark.
Sune Boris NygårdDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Ulrik LademannDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Jan StenvangDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Siqi LiuBeijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Anja Thoe FuglsangTransport Biology section, Department of Plant and Environmental Sciences, University of Copenhagen, Denmark.
Nils BrünnerDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
José Manuel Afonso MoreiraDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.ORCID 0000-0002-9944-1214
University of Copenhagen · DKChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue inhibitor of metalloproteinases-1 (TIMP-1) regulates the proteolytic activity of matrix metalloproteinases (MMPs), playing an important role in the homeostasis of the extracellular matrix. Beyond its well-known role in tissue maintenance, TIMP-1 has been associated with multiple MMP-independent cytokine-like functions. The protein structure of TIMP-1, with two distinct domains, one interacting with MMPs and another able to bind multiple partners, provides a rationale for this multifunctionality. The identification of CD63 as a cell surface receptor for TIMP-1, able to mediate intracellular signaling through the Erk/MAPK axis, provided a molecular basis for the role of TIMP-1 in cellular signaling. However, several lines of evidence suggest that TIMP-1 may be able to associate with many interaction partners, thus attaining multiple functions. To enable the identification of previously unknown interaction partners that may underpin the core cellular functions of TIMP-1, known as well as unknown, we performed a yeast two-hybrid screening using a mammary gland complementary DNA (cDNA) library. We report here the identification of multiple interactors, including MHC class II-associated invariant chain γ (CD74). We verified that CD74 interacts with TIMP-1 in breast cancer cells and that this interaction contributes to cellular internalization of TIMP-1 and mediates intracellular signaling through the Akt signaling axis in breast cancer cells. These data provide new insights into the complex nature of the functions of TIMP-1 and their potential mechanistic basis.

Indexed as

Breast NeoplasmsTissue Inhibitor of Metalloproteinase-1Antigens, Differentiation, B-LymphocyteCell MembraneFemaleHistocompatibility Antigens Class IIHumansMatrix MetalloproteinasesProtein BindingAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIinvariant chainMatrix MetalloproteinasesTissue Inhibitor of Metalloproteinase-1breast cancercell signalinginvariant chain (CD74)receptorTIMP-1 interaction

Identifiers

PMID37081824
PMCPMC10399710
OpenAlexW4366602674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.